Related Experiment Videos
Antibacterial prophylaxis in chronic granulomatous disease. A case report
Insights
Long-term prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) effectively prevents infections in children with chronic granulomatous disease (CGD). This case study highlights TMP-SMX
Area of Science:
- Immunology
- Pediatrics
- Genetics
Background:
- Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by defective phagocyte function, leading to recurrent severe infections.
- Controlled studies on the long-term efficacy of prophylactic treatment in childhood CGD are lacking.
- A novel variant of CGD, presenting with features of both childhood and adult types, was identified.
Observation:
- A 15-year-old male with CGD since infancy experienced continuous illness and frequent hospitalizations due to severe bacterial infections.
- The patient's condition demonstrated a unique combination of clinical, laboratory, and genetic characteristics.
- Infection recurrence was directly linked to non-compliance with prophylactic medication.
Findings:
- Initiation of long-term prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) at age 13 resulted in a near-complete absence of infections.
- The patient's clinical course served as a self-controlled demonstration of TMP-SMX efficacy.
- TMP-SMX prophylaxis was highly effective in maintaining an infection-free state, with relapses occurring only during periods of non-adherence.
Implications:
- Antimicrobial prophylaxis, specifically with TMP-SMX, is a crucial and effective strategy for managing pediatric chronic granulomatous disease.
- This case underscores the importance of consistent medication adherence for patients with CGD to prevent serious infections.
- The findings support the use of TMP-SMX as a standard prophylactic regimen for children diagnosed with chronic granulomatous disease.
Abstract:
The value of long-term prophylactic treatment of chronic granulomatous disease (CGD) in childhood cannot be established with certainty, as controlled studies are not available. We describe a boy, presently 15 years old, who suffered from CGD since early infancy. By the clinical, laboratory and genetic features, this case appeared to be a new variant of CGD, combining elements of the "childhood" type with others that characterize the "adult" type of the syndrome. For years, the patient had been almost continuously ill and needed frequent and prolonged hospitalizations because of severe bacterial infections. At age 13 years, long-term prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) was instituted. With this regimen, the patient was maintained practically infection-free, relapsing only in those instances when he neglected to comply with the prophylactic regimen for 1 to 2 weeks. Thus, the patient served as his own control in demonstrating the efficacy of antimicrobial prophylaxis in CGD. The rationale for employing TMP-SMX for the prophylactic regimen is discussed.